Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]NEW YORK, March 13, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading n ...

Company Overview - Viatris Inc. is a global healthcare company that bridges the gap between generics and brands, aiming to address healthcare needs worldwide [2] - The company provides access to high-quality medicines for approximately 1 billion patients annually, covering all stages of life and various health conditions [2] - Viatris has a diverse portfolio of medicines and a unique global supply chain designed to reach patients effectively [2] Upcoming Event - Viatris will present at the Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 2 p.m. ET [1] - A live webcast of the event will be available, with an archived version accessible for a limited time after the event [1]

I'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden YARP Portfolio, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income investing. I've been charting investments since the 1980s, and I spent decades an an investment advisor and fund manager before semi-retiring in 2020. Now, this investing group is my focus. The markets tells us a story…we just have to listen! I teach subscriber ...

NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Viatris and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On February 27, 2025, Viatris ...

Core Insights - Viatris reported revenue of $3.53 billion for the quarter ended December 2024, reflecting an 8.1% decline year-over-year and a surprise of -2.04% compared to the Zacks Consensus Estimate of $3.6 billion [1] - The company's EPS was $0.54, down from $0.61 in the same quarter last year, with an EPS surprise of -5.26% against the consensus estimate of $0.57 [1] Financial Performance - Total Net Sales were $3.52 billion, below the three-analyst average estimate of $3.59 billion, marking an 8.1% year-over-year decrease [4] - Other revenues reached $12.70 million, exceeding the estimated $11.47 million, representing an 11.4% increase year-over-year [4] - Net Sales in JANZ were $334.50 million, below the average estimate of $366.35 million, reflecting a 10.2% decline year-over-year [4] - Emerging Markets Net Sales were $513 million, slightly below the estimate of $538.93 million, with a year-over-year decrease of 17.1% [4] - Developed Markets- Brands Net Sales were $1.10 billion, compared to the $1.21 billion estimate, indicating a 16.3% year-over-year decline [4] - Net Sales in Greater China were $521.80 million, slightly below the estimate of $553.04 million, but showing a 1.3% year-over-year increase [4] - Developed Markets Net Sales totaled $2.15 billion, slightly below the estimate of $2.17 billion, with a 7.5% year-over-year decline [4] - Developed Markets- Generics Net Sales were $1.04 billion, below the estimate of $1.06 billion, reflecting a significant 27.1% year-over-year decrease [4] Stock Performance - Viatris shares have returned -16.6% over the past month, contrasting with the Zacks S&P 500 composite's -2.4% change [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Shares of Viatris Inc. NASDAQ are consolidating Friday. This follows yesterday's 15% selloff. The stock was down because the company reported earnings that were below what The Street was looking for.The chart of Viatris is a good illustration of an important market dynamic. Certain price levels have more importance than others. This is why our team of technical analysts has made it our Stock of the Day.Some stock market analysts are proponents of Random Walk Theory. They believe that changes in stock prices ...

Company Overview - Viatris supplies high-quality medicines to approximately 1 billion patients globally each year[334]. - The company operates in over 165 countries with approximately 32,000 employees and has 26 manufacturing and packaging sites worldwide[335]. - Viatris has a diversified portfolio consisting of generics, iconic brands, and innovative medicines[335]. - The company has a unique global supply chain designed to reach more people when and where they need them, addressing global healthcare needs[521]. Financial Performance - For the year ended December 31, 2024, total revenues were $14.74 billion, a decrease of $687.6 million, or 4%, compared to $15.43 billion in 2023[354]. - Net sales for 2024 were $14.69 billion, down $695.6 million, or 5%, from $15.39 billion in the prior year, with a significant impact from divestitures[357]. - Gross profit for 2024 was $5.62 billion, with gross margins at 38%, down from $6.44 billion and 42% in 2023, primarily due to divestitures and impairment charges[366]. - The company reported a significant impairment charge of $184.6 million related to its equity investment in Mapi, impacting overall financial performance[375]. - U.S. GAAP net loss for 2024 was $634.2 million, compared to a net income of $54.7 million in 2023[391]. - The comprehensive loss for 2024 was $1,099.7 million, compared to comprehensive earnings of $68.5 million in 2023 and $1,061.7 million in 2022[515]. - The total equity at December 31, 2024, was $18,635.5 million, down from $20,467.4 million at the end of 2023[518]. Cash Flow and Liquidity - Net cash provided by operating activities decreased by $597.1 million to $2.30 billion in 2024, down from $2.90 billion in 2023[398]. - Net cash from investing activities increased by $2.67 billion to $1.80 billion in 2024, compared to a net cash used of $864.5 million in 2023[400]. - Net cash used in financing activities rose by $2.03 billion to $4.33 billion in 2024, compared to $2.30 billion in 2023[403]. - Cash and cash equivalents totaled $734.8 million at December 31, 2024[408]. - The company plans to continue evaluating potential acquisitions and divestitures as part of its growth strategy, which may impact future liquidity[414]. Research and Development - Research and Development (R&D) expense for 2024 was $808.7 million, expected to increase by over $100 million in 2025 due to ongoing development programs[368]. - The company expects to incur development costs for the acquired programs through 2026, with risks associated with clinical trials and regulatory approvals[351]. Legal and Regulatory Matters - The FDA issued a warning letter and import alert for the Indore manufacturing facility, affecting 11 products, with an estimated negative impact of $500 million on 2025 total revenues[346][349]. - The company has accrued approximately $384 million for legal contingencies as of December 31, 2024[428]. - The company is involved in various legal proceedings, with potential liabilities that could materially affect its financial condition and results of operations[469]. Impairments and Charges - The company recorded a goodwill impairment charge of $321.0 million during Q2 2024 related to the JANZ reporting unit, primarily due to a 1.0% increase in the discount rate[493]. - Total litigation settlements and other contingencies, net for the year ended December 31, 2024, amounted to $350.9 million, a significant increase from $111.6 million in 2023, representing a 214% increase[371]. Market and Sales Trends - The company anticipates a negative impact on sales and gross profit due to government-imposed price reductions in certain markets[342]. - Net sales in Developed Markets decreased by $322.5 million, or 3%, while Emerging Markets saw a decrease of $300.9 million, or 12%[361][364]. - On a constant currency basis, net sales from the remaining business increased by approximately $276.1 million, or 2%, driven by new product sales of approximately $582.4 million[358]. Shareholder Returns - The company declared cash dividends of $0.48 per common share for both 2023 and 2024, totaling $586.7 million and $586.7 million respectively[518]. - The company repurchased 19,244,142 shares of common stock in 2024, costing $252.5 million[518]. Future Outlook - The company expects to continue focusing on new product development and market expansion as part of its strategic initiatives moving forward[368]. - The company plans to continue exploring various strategies to unlock the value of its global platform to create shareholder value[414].

Core Insights - Viatris Inc. (VTRS) reported fourth-quarter 2024 adjusted earnings of 54 cents per share, missing the Zacks Consensus Estimate of 57 cents, and down from 62 cents in the same quarter last year [1][9] - Total revenues for the quarter were $3.53 billion, a decline of 8.5% year-over-year, and also below the Zacks Consensus Estimate of $3.6 billion [1][2] - The company’s 2025 revenue guidance is projected between $13.5 billion and $14 billion, with adjusted earnings per share expected to range from $2.12 to $2.26 [10] Financial Performance - Q4 sales totaled $3.5 billion, down 8% year-over-year, with a divestiture-adjusted operational basis showing a 1% increase [4] - Sales from Developed Markets were $2.15 billion, down 7%, missing the estimate of $2.17 billion [4] - Emerging Markets sales were $513.2 million, down 17%, also missing the estimate of $539 million [5] - JANZ sales were $334.5 million, down 10%, missing the estimate of $366 million [5] - Greater China sales totaled $521.8 million, up 1%, but still below the estimate of $553 million [5] Product Category Performance - Revenues from Brands decreased by 10% to $2.1 billion, with flat sales on a divestiture-adjusted operational basis [6] - Lipitor sales were $355.9 million, down from $379.6 million year-over-year [6] - Generics revenues were $1.3 billion, down 5%, but up 2% on an operational change basis [7] Margin and Regulatory Issues - Adjusted gross margin was 56.3%, down from 57.5% in the previous year [8] - The company received a warning letter and import alert from the FDA affecting 11 products, which is expected to negatively impact 2025 revenues by approximately $500 million [11][12] Market Reaction - Following the disappointing results, VTRS shares have dropped 4.8% year-to-date, compared to a 16.6% decline in the industry [2]

On Thursday, Viatris Inc. VTRS reported fourth-quarter 2024 sales of $3.52 billion, down 8% year over year, missing the consensus of $3.61 billion.The company reported adjusted EPS of 54 cents, missing the consensus of 57 cents.Brands’ net sales fell 10% to $2.16 billion, and Generic’s revenues decreased 5% to $1.35 billion.Also Read: CVS Health’s Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug PricesThe company generated approximately $85 million in new product revenues in the quar ...

Viatris Inc. (NASDAQ:VTRS) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Ashwani Verma - UBS Chris Schott - JPMorgan Jason Gerberry - Bank of America Umer Raffat - Evercore Balaji Prasad - Barclays Operator Good morning everyone and welcome to the Viatri ...